Global Short Bowel Syndrome Market
Global Short Bowel Syndrome Market Size Booming to Cross USD 2 Billion by 2029
Published | 03 August 2023
Global short bowel syndrome (SBS) market is flourishing because of an increasing demand for SBS drugs due to the high cost of parenteral nutrition and the growing prevalence of short bowel syndrome.
BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the global short bowel syndrome market size at USD 828.29 million in 2022. During the forecast period between 2023 and 2029, BlueWeave expects the global short bowel syndrome market size to expand at a significant CAGR of 14.05% reaching a value of USD 2,053.24 million by 2029. Major growth drivers for the global short bowel syndrome market include an increasing prevalence of gastrointestinal disorders, advancements in medical technology, and growing awareness among healthcare professionals and patients. The incidence of short bowel syndrome is rising globally, primarily due to factors such as gastrointestinal surgeries, congenital anomalies, inflammatory bowel diseases, and other conditions leading to the removal or dysfunction of a significant portion of the small intestine. This growing prevalence has created a demand for effective treatment options. Advancements in medical technology have played a crucial role in the development of innovative therapies for short bowel syndrome. These advancements encompass parenteral nutrition solutions, intestinal transplantation procedures, and intestinal rehabilitation programs, which have improved patient outcomes and are contributing to market growth. Also, pharmaceutical companies and research organizations are actively investing in research and development efforts to discover and develop new treatment options for short bowel syndrome. These initiatives aim to enhance patients' quality of life and address the existing unmet medical needs in this field. As a result, these factors are expected to drive the expansion of the global short bowel syndrome market throughout the forecast period. However, the high cost of SBS treatment and long-term complications of SBS are anticipated to restrain the overall market growth during the period in analysis.
Global Short Bowel Syndrome Market – Overview
The global Short Bowel Syndrome (SBS) market encompasses the diagnosis, treatment, and management of a condition characterized by the loss or dysfunction of a significant portion of the small intestine. It involves pharmaceutical companies, medical device manufacturers, research organizations, and healthcare providers. Key products and services include pharmacological therapies, parenteral nutrition solutions, medical devices, surgical interventions, rehabilitation programs, and support services. The market is driven by factors such as the rising prevalence of gastrointestinal disorders, advancements in medical technology, research and development investments, and the need for effective SBS management. Market players strive to develop innovative therapies and interventions to improve patient outcomes and quality of life.
Impact of COVID-19 on Global Short Bowel Syndrome Market
COVID-19 pandemic adversely affected the global short bowel syndrome market. The healthcare systems' focus on managing COVID-19 cases, disruptions in the supply chain, and restrictions on non-essential healthcare services have affected the diagnosis, treatment, and management of SBS. Clinical trials for new therapies and medical device development have been delayed or halted, impacting research and development activities. Also, the economic impact of the pandemic has affected healthcare budgets, potentially limiting patients’ access to expensive SBS treatments. However, as the situation improved, the market gradually recovered, supported by increased healthcare investments and a resurgence in research and development efforts.
Global Short Bowel Syndrome Market – By Type
By type, the global short bowel syndrome market is divided into GLP-2, Growth Hormone, and Glutamine segments. The GLP-2 (glucagon-like peptide-2) segment holds the highest share in the global Short Bowel Syndrome (SBS) market due to its effectiveness in managing the condition. GLP-2 is a hormone that plays a crucial role in promoting intestinal growth, enhancing nutrient absorption, and reducing fluid loss. It has shown promising results in clinical trials and is approved for the treatment of SBS in several regions. GLP-2 therapies, such as Teduglutide, have demonstrated the ability to reduce dependence on parenteral nutrition and improve intestinal function. The proven efficacy of GLP-2 treatments has led to their widespread adoption, contributing to the segment's dominant market share in the global SBS market.
Major players operating in the global short bowel syndrome market include Takeda, Emmaus Life Sciences, Nutricia (Danone), Merck KGaA, GlyPharma Therapeutics, Zealand Pharma, Sancilio Pharmaceuticals, Naia Pharmaceuticals, Ardelyx, Adocia, Aralez Pharmaceuticals, Shield Therapeutics, OxThera, Rhythm Pharmaceuticals, and Pivot Pharmaceuticals. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.
The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Short Bowel Syndrome Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Short Bowel Syndrome Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.
BlueWeave Consulting provides comprehensive Market Intelligence (MI) Solutions to businesses regarding various products and services online and offline. We offer all-inclusive market research reports by analyzing qualitative and quantitative data to boost the performance of your business solutions. BlueWeave has built its reputation by delivering quality inputs and nourishing long-lasting relationships with its clients. We are one of the promising digital MI solutions companies providing agile assistance to make your business endeavors successful.
BlueWeave Consulting & Research Pvt. Ltd
+1 866 658 6826 | +1 425 320 4776 | +44 1865 60 0662
- Short Bowel Syndrome Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019–2029, Segmented By Type (GLP-2, Growth Hormone, Glutamine); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies); By Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)
Publish Date: August 2023
Increasing prevalence of short bowel syndrome (SBS) and the growing demand for SBS drugs due to the high cost of parenteral nutrition are projected to propel the expansion of the global short bowel syndrome market during the forecast period between 2023 and 2029.
Relevant Press Releases
- Saudi Arabia Veterinary Vaccine Market Size Set to Grow at Significant CAGR of 8.69% to Reach USD 376.72 Million by 2029
- Global Advanced Wound Care Market Thriving: Projected to touch USD 18.4 Billion by 2027
- GCC Condom Market Size Set to Cross USD 523 Million by 2029
- Global Radiopharmaceuticals Market Thriving: Projected to touch USD 6.43 Billion by 2027, growing at the CAGR of 6.0% during the forecast period (2020-2027)
- United States Steam and Hydrogen Peroxide Biological Indicators Market Size Expands at Steady CAGR of 7.37% Touching USD 333.66 Million by 2029